Indian pharmaceutical giant, Venus Remedies Limited, has broken new ground by securing marketing authorization in Spain for meropenem, a last-resort antibiotic. The company aims to launch the antibiotic in December, targeting a 10% market share in Spain’s $6.34 million meropenem market.
Meropenem is a broad-spectrum antibiotic of the carbapenem class. It is a critical component in the treatment of severe infections, especially in hospital ICUs. Notably, meropenem is responsible for a substantial 40% of Venus Remedies’ total sales.
The company achieved this authorization through Venus Pharma GmbH, its German subsidiary. This move underscores Venus Remedies’ commitment to expanding its reach in the European market and showcasing its high-caliber manufacturing capabilities.
“Securing marketing approval for this critically important antibiotic in Spain attests to our world-class manufacturing capabilities and expertise in developing high-quality products. This move will bolster our position in the European market,” commented Saransh Chaudhary, President of Global Critical Care at Venus Remedies.
Venus Remedies has an impressive global footprint, with over 120 marketing authorizations for meropenem worldwide, including the UK, Germany, Australia, and South Africa, among others.
The company’s Executive Director, Akshansh Chaudhary, also shed light on Venus Pharma GmbH’s promising future. He stated, “With the marketing approvals for meropenem across Europe, we expect a significant increase in turnover. We are in talks for strategic alliances with multinational companies in regulated markets.”
Venus Remedies has the capacity to manufacture 24 million units of meropenem annually and is presently operating at 60% capacity, demonstrating ample room for expansion to meet global demands.
Venus Remedies is poised to make a lasting impact in Spain and beyond with meropenem. With a firm commitment to quality and innovation, Venus Remedies is setting new benchmarks in the pharmaceutical industry.